James Paul Rickey - Dec 19, 2023 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Signature
/s/ James Paul Rickey
Stock symbol
ALPN
Transactions as of
Dec 19, 2023
Transactions value $
-$215,853
Form type
4
Date filed
12/21/2023, 07:35 PM
Previous filing
Dec 18, 2023
Next filing
Jan 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Options Exercise $76.4K +15.2K $5.02 15.2K Dec 19, 2023 Direct F1
transaction ALPN Common Stock Sale -$292K -15.2K -100% $19.21 0 Dec 19, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -15.2K -96.6% $0.00 535 Dec 19, 2023 Common Stock 15.2K $5.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $19.01 to $19.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 100% of the shares underlying the option were fully vested as of April 1, 2021.

Remarks:

Senior Vice President, Chief Financial Officer and Corporate Secretary